TauRx’s tau aggregation inhibitors (TAIs) are the product of nearly 30 years of research, preclinical and clinical investigations.
The TauRx team reported encouraging Phase 2 clinical trial results in 2008 with rember®, the company’s first-generation TAI. These results suggested that a treatment targeting the tau aggregation cascade could potentially delay the progression of disease pathology and cognitive decline in mild to moderate Alzheimer’s. For more information on the Phase 2 trial, please click on the Phase 2 button below.
The company’s second-generation TAI, LMTX®, has completed three separate trials: two in Alzheimer's disease and one in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD). For more information on the Phase 3 trials, please click on the Phase 3 button below.
In collaboration with neurology researchers in North America and Europe, TauRx is about to start a clinical study called LUCIDITY, looking at the use of LMTX® in patients with mild Alzheimer’s disease. The effect of the drug in delaying the progression of the disease will be measured using FDG-PET imaging and the treatment duration will be 6 months. The study is expected to start at US clinical research sites in late 2017 and in Canada and Europe in early 2018. Information concerning participating clinics will be available soon – please check back for updates.